Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 Nov-Dec;10(6):306-14.
doi: 10.1007/s11307-008-0161-4. Epub 2008 Jul 30.

FDG-PET/CT for the evaluation of response to therapy of cutaneous T-cell lymphoma to vorinostat (suberoylanilide hydroxamic acid, SAHA) in a phase II trial

Phillip H Kuo  1 , Kacie R Carlson, Inger Christensen, Michael Girardi, Peter W Heald
Affiliations
Clinical Trial

FDG-PET/CT for the evaluation of response to therapy of cutaneous T-cell lymphoma to vorinostat (suberoylanilide hydroxamic acid, SAHA) in a phase II trial

Phillip H Kuo et al. Mol Imaging Biol. 2008 Nov-Dec.

Abstract

Introduction: Harnessing the power of molecular imaging in particular positron emission tomography (PET) to assess response to therapy in early clinical trials has the potential to yield crucial data on efficacy and streamline drug development. Vorinostat (also known as SAHA, suberoylanilide hydroxamic acid) is a histone deacetylase (HDAC) inhibitor which alters gene transcription to inhibit proliferation and promote apoptosis.

Methods: In a phase II trial of vorinostat for cutaneous T cell lymphoma (CTCL), 2-deoxy-2-[F-18]fluoro-D-glucose (FDG)-PET/computed tomography (CT) was performed on patients with both cutaneous and nodal disease. FDG-PET/CT fuses the power of metabolic imaging from FDG-PET with the anatomic detail of CT. Scans were conducted on subjects pre-therapy and during therapy.

Results: Changes in the values of FDG uptake and measurements of nodal dimensions and thickness of cutaneous lesions were tabulated. FDG-PET/CT provided an objective measure of the response (or lack thereof) of both cutaneous and nodal disease to therapy with vorinostat. The results of this study are encouraging for the potential utility of FDG-PET/CT in future trials with HDAC inhibitors for other diseases and for CTCL with other therapies.

Conclusion: Further study will be required to determine the prognostic value of the initial PET/CT scan and response on follow-up scans.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Nat Clin Pract Oncol. 2005 Mar;2(3):150-7 - PubMed
    1. Cancer Invest. 2005;23(7):635-42 - PubMed
    1. Mol Imaging Biol. 2008 Mar-Apr;10(2):74-81 - PubMed
    1. Cancer Treat Rev. 2006 May;32(3):157-65 - PubMed
    1. Haematologica. 2004 Jan;89(1):115-6 - PubMed

Publication types